Pages that link to "Q37127462"

The following pages link to SSRI adverse events: how to monitor and manage (Q37127462):

Displaying 27 items.

• Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile (Q24623483) (← links)
• A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder (Q30498105) (← links)
• Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder (Q30570337) (← links)
• Clinical management of behavioral characteristics of Prader-Willi syndrome (Q33868078) (← links)
• Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder (Q34017493) (← links)
• The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys (Q34280398) (← links)
• Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD (Q34303518) (← links)
• A META-ANALYSIS OF COGNITIVE BEHAVIOR THERAPY AND MEDICATION FOR CHILD OBSESSIVE-COMPULSIVE DISORDER: MODERATORS OF TREATMENT EFFICACY, RESPONSE, AND REMISSION. (Q34671104) (← links)
• Cognitive-behavioral treatment of persistent functional somatic complaints and pediatric anxiety: an initial controlled trial. (Q35083774) (← links)
• Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial (Q36299893) (← links)
• Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disorders (Q36873932) (← links)
• Antidepressants, metoprolol and the risk of bradycardia (Q37079028) (← links)
• Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention. (Q37257029) (← links)
• Intensive Family-Based Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder: Applications for Treatment of Medication Partial- or Nonresponders (Q37257042) (← links)
• Inflammatory bowel disease in children: psychological and psychiatric issues (Q37738377) (← links)
• The nature, assessment, and treatment of obsessive-compulsive disorder (Q37982217) (← links)
• Pediatric obsessive-compulsive disorder: a review for nursing professionals (Q38100838) (← links)
• Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial (Q38390663) (← links)
• Early childhood trichotillomania: Initial considerations on phenomenology, treatment, and future directions (Q38777446) (← links)
• Common Factors in Pediatric Psychiatry: A Review of Essential and Adjunctive Mechanisms of Treatment Outcome (Q38820952) (← links)
• Prospective relationship between obsessive-compulsive and depressive symptoms during multimodal treatment in pediatric obsessive-compulsive disorder (Q48463432) (← links)
• Assessment and medication management of paediatric obsessive-compulsive disorder. (Q48685331) (← links)
• Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial (Q48912488) (← links)
• Pharmacological treatment of anxiety disorders in children and adolescents: a review for practitioners (Q49277998) (← links)
• Anxiety and Obsessive-Compulsive Disorder (Q57090492) (← links)
• Challenges in the diagnosis and treatment of pediatric obsessive-compulsive disorder (Q61809147) (← links)
• Assessment and treatment of anxiety disorders in children and adolescents (Q83173077) (← links)